Especially for estrogen receptor-expressing (ER+) breast cancer and non-small cell lung cancer (NSCLC), there is ample evidence that Orai3 functions as an attractive therapeutic target in these pathogenic cell types. Here, ORAI3 is linked to non-small cell lung carcinoma.